|1.||Silverman, Robert H: 43 articles (04/2015 - 01/2002)|
|2.||Malathi, Krishnamurthy: 11 articles (01/2015 - 12/2004)|
|3.||Zhou, Aimin: 9 articles (12/2014 - 01/2002)|
|4.||Jha, Babal Kant: 9 articles (01/2014 - 01/2006)|
|5.||Hassel, Bret A: 8 articles (07/2014 - 03/2007)|
|6.||Dong, Beihua: 8 articles (04/2014 - 05/2003)|
|7.||De Meirleir, Kenny: 8 articles (01/2008 - 04/2002)|
|8.||Chakrabarti, Arindam: 6 articles (04/2015 - 01/2011)|
|9.||Ezelle, Heather J: 6 articles (04/2014 - 03/2007)|
|10.||Barton, David J: 5 articles (03/2015 - 04/2002)|
01/01/2014 - "Although, RNase L is generally protective against viral infections, abnormal RNase L expression and activity have been associated with a number of diseases. "
07/01/2006 - "PKR and RNase L contribute to protection against lethal West Nile Virus infection by controlling early viral spread in the periphery and replication in neurons."
03/01/2006 - "These data provide to our knowledge the first demonstration that xenotropic MuLV-related viruses can produce an authentic human infection, and strongly implicate RNase L activity in the prevention or clearance of infection in vivo. "
01/01/2014 - "Our studies suggest that during viral infections, the OAS/RNase L pathway can either enhance or suppress IFN production, depending on the cell type. "
12/15/2009 - "In this study, we determined the role of the human OAS/RNase L pathway in host defense against dengue virus (DEN) infection and assessed the antiviral potential of each isoform in the human OAS family. "
01/01/2008 - "To evaluate the implication of an abnormal activity of RNase L in the onset and development of viral induced cancers, the study was initiated by searching for germline mutations in patients diagnosed with uterine cervix cancer. "
01/01/2014 - "The expression of ABCE1 and its target protein-RNase L, were first studied in tumor tissues of OSCC and adjacent non-tumor tissues. "
10/01/2012 - "RNase L mediates critical cellular functions including antiviral, proapoptotic, antiproliferative and tumor suppressive activities. "
01/01/2012 - "Thus, while the molecular details are understood for only a subset of RNase-L activities, its regulation by small molecules and critical roles in host defense and as a candidate tumor suppressor make it a promising therapeutic target."
01/01/2012 - "Inactivation or dysregulation of RNase-L is associated with a compromised immune response and increased risk of cancer, accordingly its activity is tightly controlled and requires an allosteric activator, 2',5'-linked oligoadenylates, for enzymatic activity. "
09/01/2013 - "These studies demonstrate that CS is an important regulator of antiviral innate immunity, highlight novel roles of RNase L in CS plus virus induced inflammation, tissue remodeling, apoptosis, and cytokine elaboration and highlight pathways that may be operative in chronic obstructive pulmonary disease and mechanistically related disorders. "
03/01/2003 - "In the absence of acute infection or chronic inflammation, a high RNase L ratio could distinguish CFS patients from healthy volunteers. "
01/01/2014 - "Increased expression of RNase L or downregulation of its inhibitor (RLI) improved insulin response in mouse myogenic C2C12 cells and in primary human myotubes from normal-weight subjects treated with palmitate, a saturated free fatty acid (FFA) known to induce inflammation and oxidative stress via TLR4 activation. "
01/01/2013 - "RNase L impacts the expression of certain genes related to cell migration and inflammation such as transforming growth factor (TGF)-β, IL-1β, IL-10, CCL2 and Cox-2. "
05/01/2004 - "Our results strongly suggest that the IFN-inducible RNase L is induced by a broad range of stress-inducing signals such as double-stranded RNA (dsRNA) produced during viral infection, membrane- and osmotic shock caused by CaCl(2) and oxidative stress induced by H(2)O(2), inflammation stimulated by TNF-alpha and chemotherapy. "
|4.||Chronic Hepatitis C
11/01/2000 - "Also, the expression of the RNase L inhibitor showed a significant reduction in chronic hepatitis C (P =.0184). "
07/01/2014 - "Determination of frequency of occurrence and clinical significance ofinterleukin-28B (IL28B) and RNAse L gene polymorphism in patients with chronic hepatitis C (CHC). "
01/01/2009 - "The clinical relevance of RNase L cleavage for response to an interferon-alpha-based therapy in chronic hepatitis C is unknown. "
01/01/2009 - "Clinical relevance of the 2'-5'-oligoadenylate synthetase/RNase L system for treatment response in chronic hepatitis C."
11/01/2000 - "Intrahepatic mRNA expression of interferon-inducible antiviral genes in liver diseases: dsRNA-dependent protein kinase overexpression and RNase L inhibitor suppression in chronic hepatitis C."
06/14/2012 - "An ns2 mutant virus was unable to replicate in the liver or induce hepatitis in wild-type mice, but was highly pathogenic in RNase L deficient mice. "
06/14/2012 - "Thus, RNase L is a critical cellular factor for protection against viral infection of the liver and the resulting hepatitis."
06/14/2012 - "We show that ns2 has 2',5'-phosphodiesterase activity, which blocks the interferon inducible 2',5'-oligoadenylate synthetase (OAS)-RNase L pathway to facilitate hepatitis development. "
|2.||eIF-2 Kinase (eIF 2 Kinase)
|5.||RNA (Ribonucleic Acid)
|6.||familial Prostate cancer
|7.||Scavenger Receptors (Scavenger Receptor)
|2.||Drug Therapy (Chemotherapy)
|3.||Homologous Transplantation (Allograft)
|4.||Heterologous Transplantation (Xenotransplantation)